{
    "ticker": "ABVC",
    "name": "ABVC BioPharma, Inc.",
    "description": "ABVC BioPharma, Inc. is a biopharmaceutical company focused on the research, development, and commercialization of innovative therapeutics for the treatment of various medical conditions. Founded in 2011, ABVC is dedicated to addressing unmet medical needs through a diverse portfolio of drug candidates that emphasize safety and efficacy. The company's primary focus is on developing treatments for cancer, neurodegenerative diseases, and metabolic disorders. ABVC is advancing its proprietary drug candidates, including ABV-181, a novel treatment for Alzheimer\u2019s disease, and ABV-150, aimed at oncology applications. With a commitment to scientific excellence, ABVC collaborates with leading research institutions and utilizes cutting-edge technology to enhance its drug development processes. The company prioritizes patient-centric approaches and strives to bring new hope to patients suffering from debilitating conditions. ABVC is also actively engaged in expanding its pipeline through strategic partnerships and collaborations, ensuring a robust growth trajectory in the competitive biopharmaceutical landscape.",
    "industry": [
        "Biopharmaceuticals",
        "Healthcare"
    ],
    "headquarters": "Taipei, Taiwan",
    "founded": "2011",
    "website": "http://www.abvcbiopharma.com",
    "ceo": "Dr. Jason M. S. Chen",
    "social_media": {
        "twitter": "https://twitter.com/ABVCBioPharma",
        "linkedin": "https://www.linkedin.com/company/abvc-biopharma/"
    },
    "investor_relations": "http://www.abvcbiopharma.com/investor-relations",
    "key_executives": [
        {
            "name": "Dr. Jason M. S. Chen",
            "position": "CEO"
        },
        {
            "name": "Dr. James W. Y. Chen",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Drug Candidates",
            "products": [
                "ABV-181",
                "ABV-150"
            ]
        }
    ],
    "seo": {
        "meta_title": "ABVC BioPharma, Inc. | Innovative Biopharmaceuticals for Unmet Medical Needs",
        "meta_description": "Explore ABVC BioPharma, Inc., a biopharmaceutical company dedicated to developing innovative therapeutics for cancer, neurodegenerative diseases, and metabolic disorders.",
        "keywords": [
            "ABVC BioPharma",
            "Biopharmaceuticals",
            "Cancer Treatment",
            "Alzheimer's Disease",
            "Innovative Drugs"
        ]
    },
    "faq": [
        {
            "question": "What is ABVC BioPharma known for?",
            "answer": "ABVC BioPharma is known for developing innovative therapeutics targeting cancer, neurodegenerative diseases, and metabolic disorders."
        },
        {
            "question": "Who is the CEO of ABVC BioPharma?",
            "answer": "Dr. Jason M. S. Chen is the CEO of ABVC BioPharma, Inc."
        },
        {
            "question": "Where is ABVC BioPharma headquartered?",
            "answer": "ABVC BioPharma is headquartered in Taipei, Taiwan."
        },
        {
            "question": "What are ABVC BioPharma's main products?",
            "answer": "ABVC BioPharma's main products include ABV-181 and ABV-150, aimed at treating Alzheimer's disease and cancer, respectively."
        },
        {
            "question": "When was ABVC BioPharma founded?",
            "answer": "ABVC BioPharma was founded in 2011."
        }
    ],
    "competitors": [
        "NVS",
        "AMGN",
        "GILD"
    ],
    "related_stocks": [
        "MRNA",
        "REGN",
        "VRTX"
    ]
}